OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SURK53

Suraksha Diagnostic Ltd

Healthcare Facilities & ServicesVerified

Business Summary Suraksha Diagnostic Ltd provides diagnostic services and operates in the healthcare facilities and services industry, generating revenue primarily through laboratory testing and related healthcare services. --- # Classification Summary Suraksha Diagnostic Ltd is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a high confidence level of 0.92 according to verified market data. --- # Narrative Suraksha Diagnostic Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.42, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.1, suggesting it has sufficient short-term assets to cover its short-term liabilities, though not with a significant buffer. Free cash flow stands at INR 242.5 million, which is a positive indicator of the company's ability to generate cash after capital expenditures. In terms of profitability, the company's return on equity (ROE) is 15.07%, and its return on assets (ROA) is 9.54%. These figures are strong and suggest that the company is effectively utilizing its equity and assets to generate profits. The operating margin, calculated as operating income divided by revenue, is 18.33%, which is a key metric for assessing operational efficiency in the healthcare services industry. The company's revenue is primarily concentrated in its core diagnostic services, with no significant diversification into other segments. Geographically, the company's operations are centered in India, and there is no indication of substantial international exposure in the provided data. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes. Looking at the growth trajectory, the company's revenue for the latest period is INR 2.52 billion. While the data does not provide a multi-year growth rate, the positive free cash flow and strong ROE suggest a stable and potentially growing business. The company's capital expenditures were negative INR 420.24 million, indicating that it may have been reducing its capital investments or receiving returns from existing investments. The risk assessment for Suraksha Diagnostic Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its ability to meet short-term obligations without additional financing. However, the low dilution risk suggests that the company is not likely to issue a significant number of new shares in the near future, which is favorable for existing shareholders. Recent events and filings do not show any significant changes in the company's operations or financial strategy. The company's IR observations indicate that analysts have a neutral stance, with a mean recommendation of 3.00, which is a hold rating. There are no strong buy or buy recommendations, and only one hold recommendation, suggesting that the market is not particularly bullish or bearish on the stock at this time. --- # Key Takeaways - Suraksha Diagnostic Ltd has a strong return on equity (15.07%) and return on assets (9.54%), indicating effective use of equity and assets to generate profits. - The company's debt-to-equity ratio of 0.42 suggests a conservative capital structure with a relatively low reliance on debt financing. - The company's liquidity position is characterized as medium, with a current ratio of 1.1, indicating it has sufficient short-term assets to cover its short-term liabilities. - The company's revenue is primarily concentrated in its core diagnostic services, with no significant diversification into other segments. - Analysts have a neutral stance on the stock, with a mean recommendation of 3.00, which is a hold rating, and no strong buy or buy recommendations. --- # Rationales ```json { "margin_outlook_rationale": "The company's operating margin of 18.33% is strong, indicating efficient cost management and pricing power in the healthcare services industry.", "rd_outlook_rationale": "There is no specific information provided on the company's research and development activities or outlook.", "capex_outlook_rationale": "The company's capital expenditures were negative INR 420.24 million, suggesting a reduction in capital investments or returns from existing investments.", "revenue_outlook_rationale": "The company's revenue for the latest period is INR 2.52 billion, and while the data does not provide a multi-year growth rate, the positive free cash flow and strong ROE suggest a stable and potentially growing business.", "segment_outlook": {}, "dilution_sources": [], "dilution_near_term_probability": "low", "dilution_expected_timeframe": "no near-term pressure", "concentration_risk": "medium", "regulatory_risk": "low", "liquidity_risk_rationale": "The company's liquidity position is characterized as medium, with a current ratio of 1.1, indicating it has sufficient short-term assets to cover its short-term liabilities, though not with a significant buffer.", "credit_risk_rationale": "The company's debt-to-equity ratio of 0.42 suggests a conservative capital structure with a relatively low reliance on debt financing, which is favorable for credit risk." } ``` --- # Inversion (DS-6) ```json { "bull_to_bear_signals": [ { "signal_id": "bull-to-bear-1", "signal": "Operating margin declines by more than 10% year-over-year", "monitorable_field": "financial_snapshot.operating_income / financial_snapshot.revenue", "threshold": "yoy_pct < -10", "rationale": "A significant decline in operating margin could indicate operational inefficiencies or pricing pressures in the healthcare services industry." }, { "signal_id": "bull-to-bear-2", "signal": "Free cash flow becomes negative", "monitorable_field": "financial_snapshot.free_cash_flow", "threshold": "value < 0", "rationale": "Negative free cash flow could signal financial stress and reduced ability to fund operations or growth initiatives." } ], "bear_to_bull_signals": [ { "signal_id": "bear-to-bull-1", "signal": "Return on equity increases by more than 5% year-over-year", "monitorable_field": "valuation_snapshot.return_on_equity", "threshold": "yoy_pct > 5", "rationale": "An increase in return on equity indicates improved efficiency in using equity to generate profits." }, { "signal_id": "bear-to-bull-2", "signal": "Debt-to-equity ratio decreases by more than 10% year-over-year", "monitorable_field": "valuation_snapshot.debt_to_equity", "threshold": "yoy_pct < -10", "rationale": "A reduction in the debt-to-equity ratio suggests a more conservative capital structure and lower financial risk." } ] } ``` --- # Self Scoring (§A.8) ```json { "business_understanding_score": 0.95, "economics_quality_score": 0.90, "ten_year_visibility_score": 0.85, "competitive_landscape_visibility_score": 0.80 } ```

30-day price · SURK+76.10 (+33.4%)
Low$224.10High$316.50Close$304.05As of14 May, 00:00 UTC
Profile
CompanySuraksha Diagnostic Ltd
TickerSURK.NS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. (unavailable from LLM output)

Classification. (unavailable from LLM output)

# Business Summary Suraksha Diagnostic Ltd provides diagnostic services and operates in the healthcare facilities and services industry, generating revenue primarily through laboratory testing and related healthcare services. --- # Classification Summary Suraksha Diagnostic Ltd is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a high confidence level of 0.92 according to verified market data. --- # Narrative Suraksha Diagnostic Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.42, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.1, suggesting it has sufficient short-term assets to cover its short-term liabilities, though not with a significant buffer. Free cash flow stands at INR 242.5 million, which is a positive indicator of the company's ability to generate cash after capital expenditures. In terms of profitability, the company's return on equity (ROE) is 15.07%, and its return on assets (ROA) is 9.54%. These figures are strong and suggest that the company is effectively utilizing its equity and assets to generate profits. The operating margin, calculated as operating income divided by revenue, is 18.33%, which is a key metric for assessing operational efficiency in the healthcare services industry. The company's revenue is primarily concentrated in its core diagnostic services, with no significant diversification into other segments. Geographically, the company's operations are centered in India, and there is no indication of substantial international exposure in the provided data. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes. Looking at the growth trajectory, the company's revenue for the latest period is INR 2.52 billion. While the data does not provide a multi-year growth rate, the positive free cash flow and strong ROE suggest a stable and potentially growing business. The company's capital expenditures were negative INR 420.24 million, indicating that it may have been reducing its capital investments or receiving returns from existing investments. The risk assessment for Suraksha Diagnostic Ltd indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could affect its ability to meet short-term obligations without additional financing. However, the low dilution risk suggests that the company is not likely to issue a significant number of new shares in the near future, which is favorable for existing shareholders. Recent events and filings do not show any significant changes in the company's operations or financial strategy. The company's IR observations indicate that analysts have a neutral stance, with a mean recommendation of 3.00, which is a hold rating. There are no strong buy or buy recommendations, and only one hold recommendation, suggesting that the market is not particularly bullish or bearish on the stock at this time. --- # Key Takeaways - Suraksha Diagnostic Ltd has a strong return on equity (15.07%) and return on assets (9.54%), indicating effective use of equity and assets to generate profits. - The company's debt-to-equity ratio of 0.42 suggests a conservative capital structure with a relatively low reliance on debt financing. - The company's liquidity position is characterized as medium, with a current ratio of 1.1, indicating it has sufficient short-term assets to cover its short-term liabilities. - The company's revenue is primarily concentrated in its core diagnostic services, with no significant diversification into other segments. - Analysts have a neutral stance on the stock, with a mean recommendation of 3.00, which is a hold rating, and no strong buy or buy recommendations. --- # Rationales ```json { "margin_outlook_rationale": "The company's operating margin of 18.33% is strong, indicating efficient cost management and pricing power in the healthcare services industry.", "rd_outlook_rationale": "There is no specific information provided on the company's research and development activities or outlook.", "capex_outlook_rationale": "The company's capital expenditures were negative INR 420.24 million, suggesting a reduction in capital investments or returns from existing investments.", "revenue_outlook_rationale": "The company's revenue for the latest period is INR 2.52 billion, and while the data does not provide a multi-year growth rate, the positive free cash flow and strong ROE suggest a stable and potentially growing business.", "segment_outlook": {}, "dilution_sources": [], "dilution_near_term_probability": "low", "dilution_expected_timeframe": "no near-term pressure", "concentration_risk": "medium", "regulatory_risk": "low", "liquidity_risk_rationale": "The company's liquidity position is characterized as medium, with a current ratio of 1.1, indicating it has sufficient short-term assets to cover its short-term liabilities, though not with a significant buffer.", "credit_risk_rationale": "The company's debt-to-equity ratio of 0.42 suggests a conservative capital structure with a relatively low reliance on debt financing, which is favorable for credit risk." } ``` --- # Inversion (DS-6) ```json { "bull_to_bear_signals": [ { "signal_id": "bull-to-bear-1", "signal": "Operating margin declines by more than 10% year-over-year", "monitorable_field": "financial_snapshot.operating_income / financial_snapshot.revenue", "threshold": "yoy_pct < -10", "rationale": "A significant decline in operating margin could indicate operational inefficiencies or pricing pressures in the healthcare services industry." }, { "signal_id": "bull-to-bear-2", "signal": "Free cash flow becomes negative", "monitorable_field": "financial_snapshot.free_cash_flow", "threshold": "value < 0", "rationale": "Negative free cash flow could signal financial stress and reduced ability to fund operations or growth initiatives." } ], "bear_to_bull_signals": [ { "signal_id": "bear-to-bull-1", "signal": "Return on equity increases by more than 5% year-over-year", "monitorable_field": "valuation_snapshot.return_on_equity", "threshold": "yoy_pct > 5", "rationale": "An increase in return on equity indicates improved efficiency in using equity to generate profits." }, { "signal_id": "bear-to-bull-2", "signal": "Debt-to-equity ratio decreases by more than 10% year-over-year", "monitorable_field": "valuation_snapshot.debt_to_equity", "threshold": "yoy_pct < -10", "rationale": "A reduction in the debt-to-equity ratio suggests a more conservative capital structure and lower financial risk." } ] } ``` --- # Self Scoring (§A.8) ```json { "business_understanding_score": 0.95, "economics_quality_score": 0.90, "ten_year_visibility_score": 0.85, "competitive_landscape_visibility_score": 0.80 } ```
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$2.52B
Gross profit$2.15B
Operating income$462.0M
Net income$318.2M
R&D
SG&A
D&A
SBC
Operating cash flow$633.6M
CapEx-$420.2M
Free cash flow$242.5M
Total assets$3.34B
Total liabilities$1.22B
Total equity$2.11B
Cash & equivalents
Long-term debt$888.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$2.11B
Net cash-$888.9M
Current ratio1.1
Debt/Equity0.4
ROA9.5%
ROE15.1%
Cash conversion2.0%
CapEx/Revenue-16.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricSURKActivity
Op margin18.3%7.7% medp25 -2.4% · p75 15.5%top quartile
Net margin12.6%5.9% medp25 -3.8% · p75 12.8%above median
Gross margin85.4%45.5% medp25 31.1% · p75 62.9%top quartile
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-16.7%-7.0% medp25 -14.9% · p75 -3.2%bottom quartile
Debt / equity42.0%25.0% medp25 3.8% · p75 63.3%above median
Observations
IR observations
Mean price target285.00 INR
Median price target285.00 INR
High price target285.00 INR
Low price target285.00 INR
Mean recommendation3.00 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count1.00
Sell count0.00
Strong-sell count0.00
Mean EPS estimate6.60 INR
Mean revenue estimate2,907,000,000 INR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-14 00:20 UTC#e34c3c04
Source: analysis-pipeline (hybrid)Generated: 2026-05-29 14:59 UTCJob: 9778a3d1